Patents Examined by Elizabeth C. Kemmerer
  • Patent number: 11187704
    Abstract: The disclosure provides, inter alia, methods of detecting IL-6 signaling activity in T cells in breast cancer patients, such as breast cancer patients in remission.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: November 30, 2021
    Assignee: CITY OF HOPE
    Inventor: Peter P. Lee
  • Patent number: 11161889
    Abstract: GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein are methods for making and using GDF15 molecules.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: November 2, 2021
    Assignee: AMGEN INC.
    Inventors: YuMei Xiong, Kenneth William Walker, Murielle Marie Veniant Ellison
  • Patent number: 11142572
    Abstract: Disclosed herein are antibodies specific for erythroferrone and assays comprising the antibodies. Also disclosed are methods for using the assays for the diagnosis or monitoring of disease.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: October 12, 2021
    Inventors: Mark Westerman, Huiling Han, Vaughn Ostland
  • Patent number: 11136581
    Abstract: Contact of endothelial cells with inhibitors of inhibin and/or the alpha subunit of inhibin can be utilized to modify the activity of endothelial cell expression products including SMAD 1/5. Methods can also include inhibiting Alk1 and/or endoglin as components of inhibin-activated pathway of SMAD 1/5 signaling. Methods can be combined with other anti-angiogenesis therapies such as anti-VEGF therapies. Methods can be utilized in treatment of inhibin-expressing cancers (e.g., ovarian cancer, pancreatic cancer) as well as other pathologies such as preeclampsia and PCOS.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: October 5, 2021
    Assignee: University of South Carolina
    Inventors: Mythreye Karthikeyan, Priyanka Singh
  • Patent number: 11135240
    Abstract: The present invention provides novel biomaterial compositions and methods having a technology to improve retention of hyaluronic acid (HA). The biomaterial compositions utilize small HA binding peptides and extracellular matrix binding (ECM) peptides that are tethered to synthetic biocompatible polymers. When tethered to the polymers, the peptide region allows the polymers to bind to HA and to tissues such as cartilage. The novel biomaterial compositions can be used to coat or chemically modify cartilage or tissues with a biologically compatible polymer having HA binding peptides, which allow HA to bind to the surface of the cartilage or tissues. Methods of using same are also provided.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: October 5, 2021
    Inventors: Anirudha Singh, Shimon Unterman, Michael Corvelli, Jennifer Elisseeff
  • Patent number: 11117976
    Abstract: The present application discloses a previously unknown function of CD24 expressed on a subset of dendritic cells. The invention encompasses regulating CD24 on these cells to regulate erythropoiesis, induce EPO production and levels, increase RBC levels, and to treat, for example, stress-mediated erythropoiesis. The compositions and methods of the invention are useful, for example, in treating anemia.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: September 14, 2021
    Assignee: University of Virginia Patent Foundation
    Inventors: Thomas J. Braciale, Taeg S. Kim
  • Patent number: 11111283
    Abstract: The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: September 7, 2021
    Assignee: NOVARTIS AG
    Inventors: Kristen Johnson, Jian Shi
  • Patent number: 11104711
    Abstract: Compounds are provided herein for inducing weight loss and for treating diabetes, dyslipidemia, NASH and/or obesity. Also provided are pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions, where such compounds act as GDF15 agonists with extended time of action and other advantageous properties.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: August 31, 2021
    Assignee: Eli Lilly and Company
    Inventors: Malgorzata Donata Gonciarz, Victor H. Obungu, Richard Todd Pickard
  • Patent number: 11098113
    Abstract: The present invention relates to immunoglobulin single variable domains that bind MIF and more in particular to polypeptides that comprise or essentially consist of one or more such immunoglobulin single variable domains; to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: August 24, 2021
    Assignees: VIB VZW, Vrije Universiteit Brussel
    Inventors: Peter Vanlandschoot, Ines Cabrito, BenoƮt Stijlemans, Amanda Sparkes, Jo Van Ginderachter, Patrick De Baetselier
  • Patent number: 11098091
    Abstract: Mutant M-CSF protein, comprising ?v?3 integrin binding motif and pharmaceutical compositions comprising same, are provided. Further, use of the composition for the treatment and or prevention of diseases associated with increased bone resorption are provided.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: August 24, 2021
    Inventors: Niv Papo, Noam Levaot, Yuval Zur, Lior Rosenfeld
  • Patent number: 11090361
    Abstract: The invention features polypeptides that include an extracellular ActRlla variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRlla variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving bone damage, e.g., primary osteoporosis, secondary osteoporosis, osteopenia, osteopetrosis, facture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: August 17, 2021
    Assignee: Keros Therapeutics, Inc.
    Inventors: Jasbir S. Seehra, Jennifer Lachey
  • Patent number: 11078248
    Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. The invention further relates to compositions including a protease and a growth factor comprising a bone morphogenic protein (BMP) or a variant thereof. The invention also relates to methods of using the composition.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: August 3, 2021
    Assignee: LifeNet Health
    Inventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
  • Patent number: 11078270
    Abstract: The invention relates to negative functional modulators of erythropoietin (EPO) for use in the treatment of cancers, in the therapy of autoimmune -based and non-autoimmune based chronic inflammatory diseases, and in the treatment of patients under-going organ or tissue transplant, or for the treatment of hemophilic arthropathy, hemophilia A and B, von Willebrand disease, angiodysplasia, proliferative disorders and neurological diseases characterized in their pathogenesis by primary neuroinflammation and/or neuroinflammation secondary to other causes. Such modulators are anti-EPO antibodies and their derivatives: anti-EPO receptor antibodies (EPOR), antisense oligonucleotides, decoy DNA, decoy RNA, ribozyme, antagomir, shRNA, LNA and/or siRNAs that inhibit the expression of the gene encoding EPO or EPOR.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: August 3, 2021
    Assignee: ANDREMACON S.R.L.
    Inventors: Giovanni Marfia, Stefania Elena Navone, Giuseppe Scalvini, Laura Riboni, Rolando Campanella
  • Patent number: 11072647
    Abstract: An isoform of the TGF beta receptor II comprising a sequence of about of 80 amino acids and lacking a transmembrane domain. The isoform comprises the amino acid sequence set forth in SEQ ID No. 12. The isoform may have the amino acid sequence set forth in SEQ ID No. 2 or sequences having at least 85% sequence identity to the sequence set forth in SEQ ID No. 2. A fusion peptide is provided comprising an isoform of the TGF beta II receptor fused to a ligand, wherein a vector comprising the fusion peptide is used to treat cancer and/or hepatic fibrosis. An antibody binding the soluble isoform of the TGF beta II receptor is provided. The antibody binds the amino acid sequence shown in SEQ ID No. 12 and is used in in vitro methods.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: July 27, 2021
    Assignees: Onsejo Nacional DE Investigation Cientiticay Tecnica, Fundocion Articula
    Inventors: Ana Romo, Anabela Belen La Colla, Matias Adan Preisegger, Marcela Soledad Bertolio, Ricardo Alfredo Dewey, Pamela Daiana Vazquez, Andrea Nancy Chisari, Tania Melina Rodriguez, Benito Jorge Velasco Zamora
  • Patent number: 11065303
    Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: July 20, 2021
    Inventors: Ravindra Kumar, John Knopf
  • Patent number: 11066658
    Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: July 20, 2021
    Inventors: Udi Eyal Fima, Gili Hart
  • Patent number: 11052150
    Abstract: It is an object of the present invention to provide a pharmaceutical composition comprising an anti-fractalkine antibody that provides therapeutically effective improvement to Crohn's disease, after the administration thereof to a human subject, and a method for treating Crohn's disease. Provided is a pharmaceutical composition for treating Crohn's disease. The present pharmaceutical composition comprises an anti-fractalkine antibody and a pharmaceutically acceptable excipient, and is used, such that the anti-fractalkine antibody is intravenously administered to a human at a dose of at least 10 mg/kg of human body weight in a method for treating Crohn's disease.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: July 6, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Nobuyuki Yasuda, Kiyoshi Oketani, Hiroko Baba, Tomohisa Nakano, Masahiko Mori
  • Patent number: 11053292
    Abstract: In certain embodiments, this disclosure relates to conjugates comprising a polypeptide of GM-CSF and a polypeptide IL-4. Typically, the GM-CSF and IL-4 are connected by a linker, e.g., polypeptide. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such nucleic acids.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: July 6, 2021
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Jacques Galipeau, Jiusheng Deng
  • Patent number: 11040102
    Abstract: Discloses herein are high concentration antibody formulations comprising an anti-sclerostin immunoglobulin and an acetate salt and/or an acetate buffer and methods of use.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: June 22, 2021
    Assignee: AMGEN INC.
    Inventor: Timothy David Osslund
  • Patent number: 11034768
    Abstract: The invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods featured in the invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: June 15, 2021
    Inventors: Nikhil Amin, Neil Graham, Gianluca Pirozzi, Ariel Teper